Last updated 18 days ago

A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)

250 patients around the world
Available in Brazil, Argentina, United States
Janssen Research & Development, LLC
5Research sites
250Patients around the world
This study is for people with
Bladder Cancer
Non-muscle-invasive bladder cancer
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Sites
Centro Médico Privado CEMAIC - Córdoba
Centro Médico Privado CEMAIC - Córdoba
Recruiting
Monseñor Pablo Cabrera 2941, Córdoba
Centro Urológico Profesor Bengió - Córdoba
Centro Urológico Profesor Bengió - Córdoba
Recruiting
Urquiza 358, 1er Piso.
Hospital Privado de la Comunidad
Recruiting
Córdoba 4545, Mar del Plata, Buenos Aires
Centro Gutman
Recruiting
Av. Sta. Fe 3233, C1425BGH Cdad. Autónoma de Buenos Aires, Argentina
AC Camargo Cancer Center
Recruiting
São Paulo, 01509-001
Trialtech
About usOur missionOur teamPartnersFAQs
Medical newsLatest newsStudiesInterviewsTestimonials
ProductsUEPM OncoUEPM Physicians
LinksDownloads
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy